The AMPLIFY-BD readout is a genuine proof-of-concept milestone for a first-in-class mechanism, but it is not a de-risked asset. Elunetirom — an oral, brain-penetrant CNS thyroid hormone receptor agonist — achieved a 16.8-point mean reduction in HAMD-17 (p<0.001) at Week 6 with 75% response and 50% remission rates and no serious treatment-related adverse events in a randomized Phase 2 trial. The rapid onset by Week 2 is clinically meaningful in a population where delayed antidepressant response carries real morbidity risk. [1] FDA Fast Track designation confirms regulatory recognition of unmet need and enables rolling review. What the announcement does not provide is the single most important number: the placebo arm's HAMD-17 change and response/remission rates. Without the drug-placebo delta, the net treatment effect attributable to elunetirom cannot be determined from the press release. The adjunctive design compounds this: patients were on background mood stabilizers or antipsychotics whose composition is not reported, meaning the observed 16.8-point reduction reflects elunetirom plus unspecified background therapy, not elunetirom alone. No mechanistic precedent exists — CNS thyroid hormone receptor agonism has no prior psychiatric approval — so no regulatory template anchors Phase 3 expectations. HTA bodies, per the CADTH cariprazine bipolar depression review (mechanistically distinct, flagged), have required cross-study replication, active comparator data, and maintenance evidence before granting favorable reimbursement recommendations; a single 6-week Phase 2 trial does not approach that bar. [2] The sharpest risk is Phase 2-to-Phase 3 attrition in a CNS indication with no mechanistic precedent and an uncharacterized long-term thyroid hormone receptor safety profile.
AMPLIFY-BD is a randomized Phase 2 trial reporting p<0.001 on HAMD-17 at Week 6, but placebo arm data are not disclosed, no Phase 3 data exist, and no mechanistic precedent (CNS thyroid hormone receptor agonism in psychiatry) has been established to anchor replication probability.
| Indication | Bipolar I or bipolar II depression |
| Drug | Elunetirom |
| Mechanism of Action | CNS thyroid hormone receptor agonist |
| Company | Autobahn Therapeutics, Inc. |
| Trial Phase | Phase 2 |
| Trial Acronym | AMPLIFY-BD |
| Category | Clinical Trial Event |
| Sub Category | Topline Results Positive |
| Therapeutic Area | Neuroscience |
| Primary Endpoint | Change in Hamilton Depression Rating Scale (HAMD-17) total score from baseline to Week 6 |
| Key Secondary Endpoints | Changes in HAMD-17 at Weeks 2 and 4, response and remission rates, and changes in HAMD-6, HAMD-29, CGI-BP-S, PGI, SDS, and SDQ |
| Patient Population Size | 21 adults |
| Patient Population | Adults with bipolar I or bipolar II disorder experiencing a moderate-to-severe major depressive episode |
| Follow-up Duration | Six weeks |
| HAMD-17 Reduction (Week 6) | 16.8-point mean reduction (p<0.001) |
| Response Rate (Week 6) | 75% |
| Remission Rate (Week 6) | 50% |
| Regulatory Designation | Fast Track designation |
| NCT ID (MDD Trial) | NCT06633016 |
Autobahn's Elunetirom Shows Positive Phase 2 Data in Bipolar Depression
Autobahn Therapeutics announced positive topline data from its Phase 2 AMPLIFY-BD trial evaluating elunetirom as an adjunctive treatment for bipolar I or bipolar II depression. Elunetirom, an oral, brain-penetrant CNS thyroid hormone receptor agonist, achieved statistical significance across primary and key secondary depression endpoints. The trial demonstrated a clinically meaningful 16.8-point mean reduction in HAMD-17 score (p<0.001) at Week 6, with a rapid onset of action by Week 2. It also showed high response (75%) and remission (50%) rates at Week 6, alongside a favorable safety and tolerability profile with no serious treatment-related adverse events. Elunetirom recently received U.S. FDA Fast Track designation for bipolar depression.
- Elunetirom demonstrated rapid and robust antidepressant effects, achieving a statistically significant and clinically meaningful 16.8-point mean reduction in HAMD-17 score (p<0.001) at Week 6. This rapid onset was evident by Week 2 with a 9.7-point reduction (p<0.001) and continued to Week 4 with a 13.7-point reduction (p<0.001), indicating a sustained antidepressant effect.
- The trial reported high response and remission rates at Week 6, with 75% of patients achieving a ≥50% reduction in HAMD-17 score and 50% achieving a HAMD-17 total score ≤7. Additionally, elunetirom showed broad symptomatic and functional benefits across various clinical assessments and patient-reported measures, including HAMD-6, HAMD-29, CGI-BP-S, PGI, SDS, and SDQ, reflecting improvements in key depression domains.
- Elunetirom exhibited a favorable safety and tolerability profile, with all treatment-related adverse events being mild to moderate and no serious treatment-related adverse events reported. Furthermore, neuroimaging data revealed statistically significant changes in functional connectivity in brain regions relevant to depression, providing objective evidence of enhanced brain network connectivity and neuroplastic remodeling, consistent with its CNS-targeted thyroid hormone receptor agonism mechanism.
Addressing the Significant Unmet Needs in Bipolar Depression
Bipolar depression remains one of the most clinically complex and undertreated conditions in psychiatry, with misdiagnosis and pharmacological mismanagement representing persistent systemic failures. Up to 64% of depression-related clinical encounters occur in primary care, where bipolar depression is frequently misidentified as unipolar depression — leading to treatment strategies that are, at best, ineffective and, at worst, harmful.
Diagnostic misidentification drives mistreatment. Misdiagnosis of bipolar depression as unipolar depression is common in both primary care and psychiatry. This routinely results in the use of unopposed monoamine antidepressants, which are often ineffective for bipolar depression and may cause detrimental consequences including treatment-emergent hypomania/mania, rapid cycling, or increased suicidality.
Antidepressant use carries meaningful risk of affective switch. Data from the STEP-BD program found that among 338 subjects with prior antidepressant treatment, 44% reported at least one switch into mania, hypomania, or a mixed episode within the first 12 weeks of antidepressant initiation. Significantly increased switch risk was identified with tricyclic antidepressants (OR = 7.80; 95% CI, 1.56 to 28.9), serotonin reuptake inhibitors (OR = 3.73; 95% CI, 1.98 to 7.05), and bupropion (OR = 4.28; 95% CI, 1.72 to 10.6).
Adjunctive antidepressant therapy demonstrates limited incremental efficacy. In a double-blind, placebo-controlled study, 23.5% of subjects receiving a mood stabilizer plus adjunctive antidepressant achieved durable recovery (8 consecutive weeks of euthymia), compared with 27.3% receiving a mood stabilizer plus placebo (P = 0.40). Modest nonsignificant trends favored the mood stabilizer plus placebo group across secondary outcomes.
Non-response to evidence-based treatments is common and persistent. Among patients with bipolar depression who did not respond after 6 weeks of treatment with lithium or quetiapine — representing an adequate bipolar depression trial — only one-third responded by 24 weeks. For those without response at 8 weeks, only 29% responded and 24% remitted by week 24, underscoring the need for better treatment alternatives for non-responders.
Approved pharmacological options remain limited, and side effect burden threatens adherence. Only four agents — cariprazine, fluoxetine/olanzapine, lurasidone, and quetiapine — are approved to treat bipolar depression. Side effects including weight gain, metabolic dysregulation, sedation/somnolence, and akathisia are common across mood stabilizers and atypical antipsychotics, and weight gain and sedation in particular negatively affect treatment adherence. Endocrine and metabolic comorbidities may further reduce the likelihood of positive clinical responses to pharmacologic therapies.
Evidence base for treatment guidance remains insufficient. Present treatment strategies are limited by insufficient large randomized controlled trials, an inadequate understanding of the neuropathology of bipolar illnesses, and a lack of tailored medications — particularly concerning bipolar II disorder. The effectiveness and recommendation of antidepressants in bipolar depression remain controversial because of insufficient data, and there are fewer clinical guidelines available compared with unipolar depression.
Unpacking Elunetirom's Novel MoA and AMPLIFY-BD Trial Design
Several randomized, placebo-controlled trials have evaluated pharmacological interventions for bipolar I and bipolar II depression across a range of designs, durations, and primary endpoints. The studies span monotherapy and adjunctive approaches, with the Montgomery-Åsberg Depression Rating Scale (MADRS) serving as the predominant primary efficacy measure across trials.
| Trial / Agent | Population | Design | Duration | Primary Endpoint | Key Secondary Endpoints | Primary Result |
|---|---|---|---|---|---|---|
| Lurasidone (adjunctive) + lithium or valproate | Bipolar I depression | Randomized, double-blind, placebo-controlled | 6 weeks | Change from baseline in MADRS total score | CGI-BP depression severity score; anxiety symptoms; quality of life; functional impairment | Lurasidone significantly reduced mean MADRS total score vs. placebo (−17.1 vs. −13.5; effect size = 0.34) |
| Lurasidone (monotherapy, mixed features post hoc) | Bipolar I depression with/without mixed features (YMRS ≥ 4) | Post hoc analysis of randomized, double-blind, placebo-controlled trial | 6 weeks | Change from baseline in MADRS total score to week 6 | Treatment-emergent hypomania/mania rates | Significant MADRS reduction in mixed features group (−15.7 vs. −10.9; P = .001; effect size, 0.48) and without mixed features (−15.2 vs. −10.8; P = .002; effect size, 0.48) |
| Olanzapine / OFC (mixed depression post hoc) | Bipolar I depression with mixed features | Post hoc analysis of 8-week, double-blind, placebo-controlled trial | 8 weeks | ≥50% reduction in MADRS score with <2 concurrent manic/hypomanic symptoms | Switching to mania/hypomania (YMRS ≥ 15); dropout rates | OFC vs. placebo in mixed depression: OR = 3.91 (95% CI, 1.80–8.49); olanzapine vs. placebo: OR = 1.95 (95% CI, 1.14–3.34) |
| Adjunctive ziprasidone + mood stabilizer | Bipolar I depression | Randomized, double-blind, placebo-controlled | 6 weeks | Change from baseline in MADRS total score to week 6 | Change from baseline in CGI-S score | No significant difference vs. placebo (−13.2 vs. −12.9; P = .792) |
| Lumateperone monotherapy (28 mg and 42 mg) | Bipolar I or II depression | Phase 3, randomized, double-blind, placebo-controlled (1:1:1) | 6 weeks (to Day 43) | Change from baseline in MADRS total score at Day 43 | Time to first sustained response (≥50% MADRS reduction) | Neither dose achieved significant improvement vs. placebo (28 mg LSMD vs. placebo: 0.9; 42 mg: −1.0; P > 0.05) |
| Pramipexole + mood stabilisers (PAX-BD) | Treatment-resistant bipolar depression | Multicentre, randomized, double-blind, placebo-controlled | 12 weeks (primary); 48 weeks (secondary) | Depression: Quick Inventory for Depressive Symptomatology (QIDS) at 12 weeks | Anxiety (GAD-7); psychosocial function (WSAS); hypomania/mania (Altman Scale); tolerability (TSQM); quality of life (EQ-5D-5L) | Greater depressive symptom reduction with pramipexole vs. placebo [4.4 vs. 2.1; d = −0.72] but not statistically significant (95% CI −0.4 to 6.3; p = 0.087) |
| Lamotrigine augmentation (treatment-resistant) | Treatment-resistant depressive disorder (MDD, bipolar I, bipolar II) | Prospective, open-label | 8 weeks | Percent improvement in MADRS score at week 8; predictive value of week 4 partial response | Not reported | ≥16% MADRS improvement at week 4 significantly predicted week 8 response (18/26 vs. 1/25 responders; p < 0.001) |
| Lamotrigine + quetiapine (CEQUEL reanalysis) | Bipolar I or II depression | Randomized, double-blind, placebo-controlled (101 lamotrigine; 101 placebo) | 52 weeks | Change in QIDS-SR16 scores | Classification accuracy over time | Mean QIDS-SR16 difference at weeks 10–14: −1.6317 (P = .09); at weeks 48–52: −2.0032 (P = .09); consistent classification accuracy achieved at week 44 |
| Minocycline and/or celecoxib + TAU | Bipolar I or II depression (current major depressive episode) | Multicentre, randomized, double-blind, placebo-controlled, factorial design | 12 weeks | Mean change from baseline in Hamilton Depression Scale score at week 12 | CGI; PHQ-9; GAD-7; C-reactive protein | Protocol only (trial ongoing at publication) |
AMPLIFY-BD: Rapid, Robust Efficacy and Favorable Safety for Elunetirom
Several recent randomized controlled trials have examined pharmacological and neuromodulatory interventions for bipolar depression, offering meaningful data on both efficacy and tolerability. A pooled controlled analysis of adjunctive mixed d-amphetamine/l-amphetamine salt (MAS) and lisdexamfetamine (LDX) enrolled 57 bipolar-depressed participants (BD-I: n = 23; BD-II: n = 34) across two 8-week, placebo-controlled trials. Participants receiving adjunctive LDX/MAS demonstrated a mean MADRS reduction of 54.6% versus 25.6% for placebo (95% CI: 9.1, 48.9; p = 0.005), with significantly higher response rates (65.7% vs. 16.7%; p < 0.001), remission rates (48.8% vs. 15.3%; p = 0.007), and CGI-BP improvement rates (65.0% vs. 23.5%; p = 0.001). Critically, no between-group difference in Young Mania Rating Scale (YMRS) scores was observed at baseline or endpoint (p ≥ 0.36), indicating no increased risk of treatment-emergent mania or hypomania in this carefully selected population.
A randomized, double-blind, placebo-controlled study of olanzapine monotherapy (5–20 mg/day; n = 343 active, n = 171 placebo) over 6 weeks in patients with bipolar I depression demonstrated significantly greater improvement on the MADRS (least-squares mean change: −13.82 vs. −11.67; P < 0.04), as well as on HRSD-17, YMRS, and all CGI-BP subscale scores versus placebo. Olanzapine also produced significantly higher rates of response and remission (P ≤ 0.05), though not recovery. On the safety side, olanzapine was associated with significantly greater mean increases in weight, fasting cholesterol, and triglycerides (P < 0.01), and significantly more patients gained ≥7% body weight (P < 0.001). A subsequent network meta-analysis of phase 3 trials in Japan, which also evaluated lurasidone and quetiapine extended-release (QUE-XR) alongside olanzapine, confirmed that olanzapine was superior to placebo in both response rate (risk ratio: 0.84; 95% credible interval: 0.71, 0.99) and remission rate (0.87; 0.77, 0.99), with its safety profile characterized by higher incidence of somnolence and ≥7% weight gain, and increases in body weight, total cholesterol, LDL cholesterol, and triglyceride levels relative to placebo.
A single-center, double-blind trial examined transcranial direct current stimulation (tDCS) combined with quetiapine in treatment-naive bipolar depression patients with suicidal ideation, randomizing participants to active (n = 16) or sham (n = 15) tDCS over the left dorsolateral prefrontal cortex for three consecutive weeks. Active tDCS was superior to sham on the Beck Scale for Suicidal Ideation (BSSI) as early as Day 3, with the effect sustained across the treatment period; response and remission rates on the BSSI were also higher in the active arm. However, no statistically significant difference between active and sham tDCS was observed on HDRS-17 or MADRS scores, indicating an antisuicide effect without a demonstrated antidepressant effect. The intervention was well tolerated, with all reported adverse reactions mild and limited to transient scalp discomfort.
Elunetirom's Strong Signal: Reshaping Bipolar Depression Treatment
The recent positive topline data from Autobahn Therapeutics' Phase 2 AMPLIFY-BD trial for elunetirom represents a compelling advancement in the challenging field of bipolar depression. As an oral, brain-penetrant CNS thyroid hormone receptor agonist, elunetirom introduces a novel mechanism of action, moving beyond conventional neurotransmitter-focused treatments. Research indicates that thyroid hormone receptors, including TRalpha and TRbeta, are integral to various CNS functions, from neurogenesis to the regulation of complex behaviors, suggesting a robust scientific foundation for this therapeutic approach.
The trial's results are particularly striking:
A clinically meaningful 16.8-point mean reduction in HAMD-17 scores at Week 6.
A rapid onset of action, with significant improvements observed as early as Week 2.
High response rates of 75% and remission rates of 50% at Week 6.
A favorable safety and tolerability profile, with no serious treatment-related adverse events reported.
These outcomes, coupled with the recent U.S. FDA Fast Track designation, position elunetirom as a potentially transformative adjunctive therapy. The rapid symptom improvement addresses a critical unmet need for patients experiencing acute depressive episodes. However, as with any promising Phase 2 asset, important considerations remain. The precise selectivity of elunetirom for specific thyroid hormone receptor subtypes and its long-term safety profile, particularly concerning potential systemic thyroid effects or CNS-specific adverse events, will require thorough investigation in larger Phase 3 studies. Furthermore, the evolving landscape of adjunctive treatments for bipolar depression, which includes other novel pharmacological and non-pharmacological interventions, means elunetirom will need to clearly demonstrate its unique benefits to secure a strong market position. Nevertheless, these initial data offer a strong signal that targeting central thyroid hormone pathways could unlock a new era of more effective and rapid-acting treatments for bipolar depression.
Frequently Asked Questions
References
- [1] Chou SP, Goldstein RB et al.. The Epidemiology of DSM-5 Nicotine Use Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions-III. The Journal of clinical psychiatry. 2016 Oct. 27135834
- [2] Benazzi F, Berk M et al.. Olanzapine/fluoxetine combination for the treatment of mixed depression in bipolar I disorder: a post hoc analysis. The Journal of clinical psychiatry. 2009 Oct. 19906346
- [3] Jawad MY, Alnefeesi Y et al.. Lumateperone for the Treatment of Adults With Schizophrenia: a Systematic Review. Current psychiatry reports. 2022 Aug. 35802228
- [4] Lloyd LC, Giaroli G et al.. Bipolar depression: clinically missed, pharmacologically mismanaged. Therapeutic advances in psychopharmacology. 2011 Oct. 23983940
- [5] Husain MI, Chaudhry IB et al.. Minocycline and celecoxib as adjunctive treatments for bipolar depression: a study protocol for a multicenter factorial design randomized controlled trial. Neuropsychiatric disease and treatment. 2017. 28031712
- [6] Frye MA, Helleman G et al.. Correlates of treatment-emergent mania associated with antidepressant treatment in bipolar depression. The American journal of psychiatry. 2009 Feb. 19015231
- [7] Kishi T, Yoshimura R et al.. Lurasidone, olanzapine, and quetiapine extended-release for bipolar depression: A systematic review and network meta-analysis of phase 3 trials in Japan. Neuropsychopharmacology reports. 2020 Dec. 32902200
- [8] Correll CU, Durgam S et al.. Lumateperone monotherapy for major depressive episodes associated with bipolar disorder: efficacy and safety in a randomized placebo-controlled trial. International clinical psychopharmacology. 2026 Mar 1. 40694062
- [9] Lam RW, Teng MY et al.. Light Therapy for Patients With Bipolar Depression: Systematic Review and Meta-Analysis of Randomized Controlled Trials. Canadian journal of psychiatry. Revue canadienne de psychiatrie. 2020 May. 31826657
- [10] Keck PE Jr. Monitoring pharmacotherapy response, safety, and tolerability to enhance adherence in bipolar disorder. The Journal of clinical psychiatry. 2014 May. 24922490
- [11] Sachs GS, Nierenberg AA et al.. Effectiveness of adjunctive antidepressant treatment for bipolar depression. The New England journal of medicine. 2007 Apr 26. 17392295
- [12] Sancaktar M, Elboğa G et al.. Comparative response patterns and tolerability of high-frequency rTMS in unipolar versus bipolar depression: a retrospective naturalistic study. Nordic journal of psychiatry. 2026 Aug. 42400378
- [13] Sachs GS, Ice KS et al.. Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial. The Journal of clinical psychiatry. 2011 Oct. 21672493
- [14] Wang D, Guo X et al.. Efficacy and Safety of Transcranial Direct Current Stimulation as an Add-On Trial Treatment for Acute Bipolar Depression Patients With Suicidal Ideation. CNS neuroscience & therapeutics. 2024 Oct. 39385316
- [15] Tohen M, McDonnell DP et al.. Randomised, double-blind, placebo-controlled study of olanzapine in patients with bipolar I depression. The British journal of psychiatry : the journal of mental science. 2012 Nov. 22918966
- [16] Maneeton N, Maneeton B et al.. Quetiapine monotherapy in acute phase for major depressive disorder: a meta-analysis of randomized, placebo-controlled trials. BMC psychiatry. 2012 Sep 27. 23017200
- [17] Köhler-Forsberg O, Sloth KH et al.. Response and remission rates during 24 weeks of mood-stabilizing treatment for bipolar depression depending on early non-response. Psychiatry research. 2021 Nov. 34500184
- [18] Köhler S, Bauer M et al.. [Pharmaceutical treatment of bipolar depression. Evidence from clinical guidelines and treatment recommendations]. Der Nervenarzt. 2014 Sep. 24170252
- [19] Moteshafi H, Zhornitsky S et al.. Comparing tolerability of olanzapine in schizophrenia and affective disorders: a meta-analysis. Drug safety. 2012 Oct 1. 22967188
- [20] McIntyre RS, Cucchiaro J et al.. Lurasidone in the treatment of bipolar depression with mixed (subsyndromal hypomanic) features: post hoc analysis of a randomized placebo-controlled trial. The Journal of clinical psychiatry. 2015 Apr. 25844756
Contact Us
Address
One Research Ct, Suite 450
Rockville, MD 20850
For General Inquiry
info@pienomial.com
